Exosens Stock Breaks Its Resistance at €66.65 and Accelerates in Defense Sector
The French specialist in night vision and imaging technologies for defense soars midday, among the top gainers in the SBF 120. The stock crosses a technical threshold monitored for several sessions, following a series of recent industrial announcements. The bullish momentum in the Parisian defense sector provides a favorable backdrop.
The Stock Breaks Its Resistance at €66.65, Marking a Nearly 58% Increase Over the Year
Exosens stock jumps 5.91% to €67.20 at midday, among the strongest rises in the SBF 120 while the index itself is down 0.25%. The stock has crossed its session resistance at €66.65 and remains above it, validating the momentum that started a week ago (+9.45%). The movement is part of a broader upward trend: the performance reaches 7.87% over three months and 57.56% over a year. The price is now significantly above its three moving averages, with a gap of 28.32% from the MM200 (€52.37). The RSI at 53 remains in the neutral zone, which leaves room before an overbought configuration, and the MACD has crossed back above its signal line, consistent with the intra-session breakthrough.
Recent Industrial Announcements Fuel the Momentum in the Defense Sector
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The rebound occurs following a new pivotal announcement: on May 26, Exosens announced its integration into the European SPIRIT project, aimed at developing next-generation infrared detection technologies and strengthening European strategic autonomy in defense. This announcement extends a series of dense industrial news, following the integration of Micro Pore Optics on the ESA's SMILE mission in May and the announced doubling of the production capacity of cooled infrared cameras for fiscal year 2026.
The sectoral context also plays a role: several French defense stocks are leading the SBF 120, with Thales up 2.49% and Exail Technologies 7.31%. According to the consensus of analysts surveyed, the stock is trading at about 35.7 times the expected earnings for the current fiscal year and 30.2 times those of the following year. With the validated crossing of the €66.65 resistance, the next technical level to watch is beyond recent highs.
Porté par une dynamique commerciale soutenue, en particulier sur les marchés de la Défense et de la Surveillance, ainsi que par une solide exécution opérationnelle
Risks mentioned
Charge de dépréciation de la marque de 28,2 M€ pesant sur le résultat net publié, en baisse de 45,0 %
Incertitudes persistantes sur la recherche scientifique pesant sur la demande en Sciences de la Vie
Contraction de 60 points de base de la marge brute du segment Détection & Imagerie (mix produits)
Opportunities identified
Attribution par l'US Army du contrat IDIQ BiNOD ouvrant le marché américain de la défense
Plan d'expansion de +40 % des capacités de production d'ici 2027, premiers bénéfices au S2 2026
Acquisition d'Emberion, capteurs infrarouges SWIR à points quantiques
Outlook / guidance
Expected revenue: 530 millions d'euros
Expected EBITDA: 173 millions d'euros
Management commentary: chiffre d'affaires compris entre 520 millions d'euros et 540 millions d'euros ; • EBITDA ajusté compris entre 168 millions d'euros et 178 millions d'euros
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
